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ABSTRACT 24 
Single doses of resveratrol have previously been shown to increase cerebral blood flow (CBF) with 25 
no clear effect on cognitive function or mood in healthy adults. Chronic resveratrol consumption 26 
may increase the poor bioavailability of resveratrol or otherwise potentiate its psychological effects. 27 
In this randomised, double-blind, placebo-controlled, parallel-groups study a total of 60 adults aged 28 
between 18-30yrs received either placebo or resveratrol for 28 days. On the 1st and 28th day of 29 
treatment the performance of cognitively demanding tasks (Serial subtractions, Rapid Visual 30 
Information Processing and 3-Back) (N= 41 complete datasets) were assessed, alongside blood-31 
pressure (N= 26) and acute (Near-infrared Spectroscopy [NIRS]) and chronic (Trans-Cranial 32 
Doppler [TCD]) measures of CBF (N= 46). Subjective mood, sleep quality and health 33 
questionnaires were completed at weekly intervals (N= 53/54). The results showed that the 34 
cognitive effects of resveratrol on day 1 were restricted to more accurate but slower Serial 35 
Subtraction task performance. The only cognitive finding on day 28 was a beneficial effect of 36 
resveratrol on the accuracy of the 3-Back task prior to treatment consumption. Subjective ratings of 37 
‘fatigue’ were significantly lower across the entire 28 days in the resveratrol condition. Resveratrol 38 
also resulted in modulation of CBF parameters on day 1, as assessed by NIRS, and significantly 39 
increased diastolic BP on day 28. Levels of resveratrol metabolites were significantly higher both 40 
before and after the day’s treatment on day 28, in comparison to day 1. These results confirm the 41 
acute CBF effects of resveratrol and the lack of interpretable cognitive effects.  42 
 43 
 44 
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 49 
 50 
 51 
 52 
 53 
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INTRODUCTION 54 
Resveratrol (3, 4’, 5 trihydroxystilbene) is a polyphenolic secondary metabolite produced within 55 
plants in response to a range of environmental stressors(1). Previous investigations in young, healthy 56 
humans have demonstrated significantly increased cerebral blood flow (CBF) after acute resveratrol 57 
supplementation(2) which is likely mediated by the ability of resveratrol to modulate nitric oxide 58 
(NO) synthesis(3). In line with this, oral consumption has been shown to enhance endothelium-59 
dependent relaxation in rats(4, 5), and improve flow-mediated dilatation in overweight/obese 60 
humans(6). An increase in blood-borne neural metabolic substrates such as oxygen(7) and glucose(8) 61 
have been shown to enhance aspects of cognitive performance in healthy, young humans. However, 62 
to date there is no evidence that cognitive function is modulated during acute, resveratrol-mediated 63 
increases in CBF. 64 
One potential explanation for this lack of cognitive effects is the rapid metabolism and poor 65 
bioavailability of oral resveratrol(9) which might reduce its potential bioactivity. Pharmacokinetic 66 
studies have demonstrated plasma Cmax levels of resveratrol metabolites between 0.9-3.7 µM 67 
following a single oral dose of 500mg resveratrol(10) with levels of the parent compound at trace, or 68 
undetectable concentrations(2, 10-13) after acute, bolus supplementation. Conversely, results from 3 69 
preclinical chemopreventive efficacy papers suggest that repeated low daily doses of resveratrol (up 70 
to 2mg/kg) are sufficient to produce peak plasma concentrations of aglycone resveratrol of up to 71 
2µM, potentially exerting beneficial chemopreventive effects(14) possibly as a result of a cumulative 72 
increase in plasma levels of resveratrol.  73 
Thus the current study investigated the effects of 28 day supplementation with 500mg resveratrol in 74 
healthy adults with the hypothesis being that daily consumption of this polyphenol, over an 75 
extended period, may increase bioavailability in terms of plasma levels, and potentiate any effects 76 
on cognitive performance and CBF. In the current study continuous wave (CW) Near-Infrared 77 
Spectroscopy (NIRS) was utilized to monitor acute changes in CBF in the prefrontal cortex during 78 
the performance of cognitive tasks that activate this brain region. This technique was combined 79 
with Trans-cranial Doppler sonography (TCD), applied to the middle cerebral artery (MCA), which 80 
provides a measure of acute and chronic changes in global CBF velocity (CBFV) and which has 81 
been converged successfully with NIRS previously (15). Resveratrol has previously been shown to 82 
interact with a number of diffuse, health related parameters such as antioxidant and anti-83 
inflammatory status(16, 17), monoamine oxidase-A and B activity(18) and Peroxisome proliferator-84 
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activated receptor gamma coactivator 1-alpha PGC-1α(19) production. Hence, the current study also 85 
assessed health, mood and sleep parameters via questionnaires.  86 
 87 
 88 
EXPERIMENTAL METHODS 89 
Participants 90 
All participants reported themselves to be in good health and free from illicit drugs, alcohol, 91 
prescription medication and herbal extracts/food supplements at each assessment. Participants 92 
confirmed that they would also abstain from the latter for the duration of the study and that any 93 
changes in medication or health status would be reported to the researcher when they occurred. 94 
Participants who had suffered a head injury, neurological disorder or neuro-developmental disorder 95 
were excluded from participation, as were those who did not have English as their 1st language, or 96 
had any relevant food allergies or intolerances, digestive problems, smoked tobacco, drank 97 
excessive amounts of caffeine (more than 600mg/day as assessed by a caffeine consumption 98 
questionnaire), took illicit social drugs, were pregnant, seeking to become so, or were breast 99 
feeding. 100 
The study received ethical approval from the Northumbria University Psychology department 101 
(within the Faculty of Health and Life Sciences) ethics committee (reference: SUB16_EW_1010; 102 
date approved 11/11/2010) and was conducted according to the Declaration of Helsinki (1964). All 103 
participants gave their written informed consent prior to their inclusion in the study. 104 
See table 1. for participant composition (broken down per analysis).  105 
 106 
 107 
 108 
Table 1. about here 109 
 110 
 111 
 112 
 113 
5 
 
Treatments 114 
Over the course of this 28 day supplementation study, participants received either 500mg pure 115 
trans-resveratrol (TransmaxTM by BiotiviaTM with a guaranteed purity of 98%. Also containing 10mg 116 
piperine per capsule), or an inert placebo (methyl cellulose), once daily; with the treatment 117 
allocation dictated by Latin square. Participants were instructed to consume their daily capsule in 118 
the morning and preferably with breakfast. 119 
Participants consumed their first and last capsule of treatment during the two lab visits and were 120 
instructed to self-supplement every day in the interim. Participants kept a treatment log during this 121 
time, noting down the time of capsule consumption every day. A treatment pot containing 32 122 
capsules was given to each participant at the end of visit 1- enough for 28 days of supplementation 123 
plus extra in case of loss/continued supplementation due to unforeseen circumstances/and to verify 124 
compliance. 125 
All treatments were administered in identical green vegetarian capsules with the BiotiviaTM logo and 126 
presented in identical white treatment pots with only the participant number to identify them. All 127 
treatments were produced by BiotiviaTM, prepared by the lead investigator and coded by a third 128 
party who had no further involvement in any aspect of the study. No member of the investigational 129 
team was aware of the contents of the capsules until a blind-data review was completed.  130 
 131 
Measures of cerebral-blood flow (CBF) 132 
Two complementary techniques were utilised: 133 
Acute changes in CBF - Near-Infrared spectroscopy (NIRS) 134 
NIRS is non-invasive brain imaging technique predicated on the absorption by oxygenated and 135 
deoxygenated haemoglobin of differing wavelengths of infra-red light, introduced through the intact 136 
scalp/skull. Continuous-wave NIRS (CW-NIRS) can be used to assess acute changes in local CBF, 137 
as indexed by concentration changes in total haemoglobin during a single continuous recording 138 
session, See(2) for full description of the methods employed here. Given that CW-NIRS generates 139 
concentration change data that is intrinsically baseline-adjusted to the concentration immediately 140 
prior to the first data point in the recording session, it cannot be used to quantify gross changes in 141 
CBF parameters that take place between two separate recording sessions. In this instance the change 142 
from baseline data generated by the NIRS system was subjected to a second  baseline adjustment by 143 
creating ‘change from baseline’ data with respect to the 10 minutes of NIRS data collected 144 
immediately prior to the treatment- this provided a more accurate baseline measure of immediately 145 
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pre-treatment NIRS parameters. All subsequent NIRS data was collapsed into 2 minute epochs (20 146 
resting period epochs spanning 0- 40 min and 20 task period epochs spanning 40- 80 min).   147 
 148 
Chronic changes in CBF - Trans-cranial Doppler sonography (TCD) 149 
Given the inability of CW-NIRS to measure chronic changes in CBF parameters, a second measure 150 
of CBF was also employed. Trans-cranial Doppler sonography (TCD) is a non-invasive method of 151 
measuring cerebral blood flow velocity (CBFV) through the basal intracerebral vessels through the 152 
intact skull(20) and was utilized at pre- and post-dose time points on day 1 and day 28. Pulses of 153 
ultrasound penetrate the skull at a number of ‘acoustic windows’, which include: temporal, orbital, 154 
foraminal and submandibular, insonating vessels at particular depths, with the returning ‘echo’ 155 
displayed as a Doppler waveform(21). The mean velocity, peak systolic velocity, diastolic velocity, 156 
and pulsatility index (all cm/sec) of the insonated vessel are provided; indicating the speed of the 157 
flow of blood and the variability of blood velocity. 158 
TCD has been utilized to investigate blood flow abnormalities in a number of haematological; e.g. 159 
stroke risk in sickle cell patients(22), and vascular; e.g. cerebrovascular reactivity in degenerative and 160 
vascular dementia(23), disorders as well as investigating the relationship between brain activity (in 161 
response to cognitive tasks) and blood flow velocity in healthy participants(24) and the CBFV 162 
response to pharmacological interventions; e.g. caffeine(25) and drugs; e.g. in cocaine abusers(26).  163 
In the current study, CBFV was measured with participants sitting in a reclined position in a quiet 164 
room. A trans-temporal acoustic window was utilized for assessment of the right middle cerebral 165 
artery (MCA) using pulsed TCD (Digi-LiteTM, RIMED) with a 2MHz probe held in place by a light, 166 
mounted head frame. This device provides mean velocity, peak systolic velocity, diastolic velocity, 167 
and pulsatility index information every 30 seconds; equating to ~10 values across the 5 minute 168 
recording utilized here, for each of the 4 aforementioned variables. These were averaged to give 1 169 
value for that time-point (pre- and post-dose on day 1 and pre- and post-dose on day 28) for 170 
statistical analysis.   171 
 172 
Cognitive tasks 173 
The computerised battery of cognitive tasks (which all, to a greater or lesser extent, activate the 174 
prefrontal cortex: Serial subtractions(27); RVIP(28); 3-Back(29)) were delivered on a laptop using the 175 
Computerised Mental Performance Assessment System (COMPASS, University of Northumbria) 176 
software, and comprised: 177 
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Serial subtractions (2 mins each of serial 7s, 13s and 17s):  178 
Rapid Visual Information Processing [RVIP] (2 mins):  179 
Both the serial subtraction and RVIP task are described in detail in(2). 180 
3-back: The 3-back version of this task was used in this paradigm, requiring participants to indicate 181 
whether the letter presented on screen was also present 3 letters back in the letter sequence. 182 
Participants must respond by pressing the ‘yes’ or ‘no’ button on the response box, to each letter, as 183 
quickly as they can. This task lasts for 2 minutes and is scored for accuracy and reaction time. 184 
 185 
Questionnaires 186 
Food consumption questionnaire: 187 
A non-validated food consumption questionnaire was utilized to collect information on the general 188 
diet of participants (e.g. ‘How many portions of fruit and vegetables did you eat on an average day 189 
in the past week?’) and specifically polyphenol/resveratrol consumption (e.g. ‘In the entire previous 190 
week, on how many occasions have you eaten a portion of berries or grapes?’). The questionnaire 191 
consisted of 13 questions with several also relating to compliance (e.g. ‘Was treatment consumed 192 
with breakfast and/or before 9:30am every day in the past week?’) and medication (‘Have you 193 
consumed any medication in the past week? If so, please state the medication, dose, when taken and 194 
for what reason.’). This researcher-created questionnaire has no reliability/sensitivity measures and 195 
was utilized solely as a tool to detect any gross changes in the consumption patterns of participants 196 
which might affect outcome measures. The researcher noted no salient dietary or medication 197 
changes across the study for any of the participants. 198 
General Health Questionnaire (GHQ): 199 
The GHQ(30) utilized in the current study was the 28-item scaled version which assesses somatic 200 
symptoms, anxiety and insomnia, social dysfunction and severe depression. The 28 items are scored 201 
from 0-3 with participants indicating the frequency or extent to which they have experienced a 202 
number of issues, such as ‘Have you recently been having hot or cold spells?’, in the previous week. 203 
The items combine to assess the 4 aforementioned sub-scales and the total possible score (when 204 
these 4 sub-scales are collated) ranges from 0- 84; with higher scores representing more negative 205 
symptoms.  206 
 207 
8 
 
Profile Of Mood States (POMS): 208 
The POMS is a well validated questionnaire of mood states and their fluctuations both in the 209 
clinical and research setting(31). Participants rated 65 adjectives (e.g. unhappy, considerate), in terms 210 
of how much they had felt each one in the past week, utilizing a 5-point scale from ‘not at all’ to 211 
‘extremely’. Scores from these 65 items (which includes 7 dummy adjectives) are combined to give 212 
6 global scores of ‘tension’, ‘depression’, ‘anger’, ‘fatigue’, ‘confusion’ and ‘vigour’. A total mood 213 
disturbance score can also be calculated by adding the scores from the first 5 of these global scores 214 
and subtracting ‘vigour’. 215 
Pittsburgh Sleep Quality Inventory (PSQI): 216 
The PSQI is a well validated subjective measure of the quality and pattern of sleep(32). The current 217 
study tailored this questionnaire to assess sleep during the past ‘week’ rather than ‘monthly’ as per 218 
the original. The PSQI assesses 7 factors: subjective sleep quality; sleep latency; sleep duration; 219 
habitual sleep efficiency; sleep disturbances; use of sleep medication and daytime dysfunction, via 220 
questions regarding sleep timings and 0-3- point scales where participants rate whether they have 221 
experienced a number of issues (e.g. ‘During the past week, how often have you had trouble 222 
sleeping because you have had bad dreams?’) from ‘not during the past week’ to ‘3 or more times in 223 
the past week’. A global sleep score is created by totalling the 7 sub-factor scores with higher scores 224 
indicating poorer sleep quality. 225 
 226 
Treatment guess 227 
During the day 28 visit participants were asked to guess which treatment they thought they had been 228 
taking for the duration of the study and to explain any reasons for that guess. 229 
 230 
Procedure 231 
This investigation required participants to attend the laboratory for an initial training/ screening 232 
session and then on 2 separate occasions, 28 days apart, for laboratory-based testing sessions. 233 
Participants were required to supplement themselves with 1 capsule per day in the interim. 234 
Upon arrival at both day 1 and day 28 lab visits participants completed 4 questionnaires: a food 235 
consumption questionnaire; the GHQ; POMS; and the PQSI. All questionnaires were answered in 236 
relation to the previous 7 days and completed every 7 days during the supplementation period. After 237 
filling in the questionnaires, participants then gave a blood pressure reading or an intravenous blood 238 
sample (15 participants provided blood samples- see below for more information and the 239 
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demographics of the 7 participants from the resveratrol condition entered into the analysis) which 240 
was immediately followed by a 5 minute rest. A 5 minute recording of cerebral perfusion in the 241 
MCA was then taken with TCD. The NIRS headband was then positioned onto the forehead of the 242 
participant to monitor CBF in the prefrontal cortex throughout the session. Once a reliable trace was 243 
identified participants commenced 20 minutes (x2 repetitions of the battery) of baseline cognitive 244 
tasks. The first of these repetitions acted as a ‘refresher’, attenuating any practice effects, and the 245 
second was utilized to create change from baseline data for the analysis of cognitive outcome data. 246 
A 10 minute rest period then followed with NIRS data averaged across this period and used as an 247 
accurate, immediately pre-treatment baseline for the calculation of change from baseline data for 248 
the post-treatment periods. During this 10-min resting period participants watched a non-arousing 249 
DVD. Participants then consumed the first day’s treatment and continued to watch the DVD for a 250 
further 40 minute absorption period. After this period a blood pressure reading was taken in those 251 
who did not provide a blood sample previously and 40 minutes of post-dose tasks commenced. 252 
After task completion a further blood pressure reading was taken from the relevant participants and 253 
followed by a short break before the 2nd TCD recording was conducted. Following the TCD 254 
recording participants were either free to leave the lab or provided a final blood sample if they were 255 
part of the aforementioned sub-section of participants. The timelines and running order of the 256 
testing sessions are shown in figure 1. 257 
 258 
Figure 1. about here 259 
 260 
 261 
Bioavailability assessment 262 
Participants:  263 
Complete sample sets comprising all 4 time-points were obtained from 15 participants (8 from 264 
placebo and 7 from resveratrol; 10 females, 5 males; mean age 19.87 years; range 18-25 years). All 265 
participants were asked, at the beginning of the study, if they would provide blood samples as part 266 
of the investigation: the above 15 participants represent those who agreed to this aspect of the study 267 
and for whom all 4 samples could be collected in full. The 7 resveratrol participants included in the 268 
analysis comprised: 6 females, 1 male; mean age 19.43 years, range 18-21 years. 269 
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Venous blood samples were collected before the days treatment was consumed and 110-minutes 270 
post-dose in this sub-sample of participants using 4.7ml monovettes (Sarstedt AG & Co) containing 271 
lithium heparin. Samples were centrifuged at 2500rpm for 15 minutes at 20oC to yield plasma, 272 
which was then stored at -80oC until analysis. 273 
The preparation of Samples and LC-MS analysis is as per a previous study conducted by this lab 274 
(33). 275 
 276 
 277 
Statistics 278 
The analyses of TCD, plasma, questionnaire, behavioural and treatment guess data were conducted 279 
with IBM SPSS Statistics 19.0 for Windows (SPSS Inc, Chicago, IL). NIRS data was analysed with 280 
Minitab 16 for Windows (Minitab Inc, State College, PA). 281 
Questionnaire data analysis: 282 
Questionnaire data (GHQ, POMS and PSQI) for each of the four post-dose weekly completions was 283 
analysed as change from baseline (the questionnaire scores obtained on day-1 prior to treatment) for 284 
each individual variable/sub-component by a mixed (Day (x4): 7, 14, 21, 28, by Treatment (x2): 285 
500mg resveratrol and placebo) ANOVA with Bonferroni corrected post-hoc student t tests 286 
conducted if a significant main and/or interaction effect was evinced here. 287 
Treatment guess analysis: 288 
Treatment guess data was analysed by Chi-Square. 289 
Trans-cranial Doppler (TCD):  290 
The raw data for each of the four TCD variables (Mean Velocity, Peak Systolic Velocity, Diastolic 291 
Velocity and Pulsatility Index) were analysed by a mixed (Treatment (x2): 500mg resveratrol and 292 
placebo, by time (x4): baseline day 1, post-dose day 1, pre-dose day 28 and post-dose day 28) 293 
ANOVA. 294 
Plasma analysis: 295 
The raw data for each of the four forms of plasma resveratrol (resveratrol-3-sulfate, resveratrol-4-296 
glucuronide, resveratrol-3-glucuronide and ‘total metabolites’; which is the sum of the three 297 
metabolites) was analysed via ANOVA with time as a factor (x4: baseline day 1, post-dose day 1, 298 
pre-dose day 28 and post-dose day 28). 299 
 300 
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Cognitive task data and Blood Pressure (BP) analysis:  301 
The cognitive task and BP measures produce data that can be analysed to assess both acute 302 
(potential treatment effects within day 1), pure-chronic (chronic treatment-related effects which 303 
have taken place across the 28 day supplementation period but prior to taking the day 28 treatment) 304 
and superimposed acute/chronic (the difference in ‘acute’ effects between day 1 and day 28) effects 305 
of resveratrol. In order to adequately analyse the ‘acute’, ‘pure chronic’ and ‘superimposed 306 
acute/chronic’ effects of the treatments 2 separate ANOVAs were conducted: 307 
1. Pure chronic effects: 308 
To ascertain if any pure chronic effects of resveratrol supplementation had taken place, pre-dose 309 
data on day 28 was converted to change from day 1 pre-dose baseline and analysed via one-way 310 
ANOVA to compare performance between treatments. 311 
2. Acute, chronic and superimposed effects: 312 
To ascertain if any acute and/or superimposed chronic effects of resveratrol supplementation had 313 
taken place, data was converted to change from baseline with respect to the pre-treatment scores on 314 
the first day of treatment (day 1) and analysed via a repeated measures ANOVA (treatment 315 
(resveratrol/ placebo, X repetition (x4 for cognitive data and x2 for BP), by day (day 1/28). 316 
Both ANOVAs were utilized in order to tease apart acute effects restricted to day 1 (treatment x day 317 
interactions with significant effects restricted to day 1), acute effects across both day 1 and day 28 318 
(main effect of treatment and/or a treatment x repetition interaction) and a superimposed 319 
acute/chronic effect (treatment x day interaction with significant effects restricted to day 28 320 
(interpreted with reference to the pure chronic ANOVA results)). If any such main and/or 321 
interaction effects were observed then Bonferroni corrected post-hoc student t tests were conducted 322 
to assess where these differences lie. This analysis plan has proven sensitivity in detecting the acute 323 
and chronic effects of ginseng in healthy, human participants previously(34). 324 
Near-Infrared Spectroscopy analysis: 325 
NIRS data was converted to ‘change from baseline’ (calculated from the 10 minute pre-treatment 326 
resting period) and averaged across 2 minute epochs during the 40 minute ‘rest/absorption’ and 40 327 
minute cognitive task performance period. Analysis of variance (treatment group x 2min epoch x 328 
day) was conducted on this data with planned comparisons of data from each epoch being made 329 
between placebo and 500mg resveratrol (resulting in 40 planned comparisons for oxy-HB, Deoxy-330 
Hb and total-Hb) using t tests calculated with the Mean Squares Error from the ANOVA(35). A 331 
significant result on this ANOVA was not used as a prerequisite for carrying out and interpreting 332 
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the planned comparisons and are, therefore, not presented here. However, in order to reduce the 333 
potential for Type I errors, all planned comparisons were Bonferroni corrected and only those 334 
planned comparisons associated with a consistent pattern of significant effects are interpreted and 335 
reported herein.  336 
 337 
 338 
RESULTS 339 
Compliance 340 
Potential compliance ranged from 0-114% (the upper limit reflecting 32 capsules consumed over 28 341 
days). Average compliance was 101% with a range of 78.5-114.3%. Data from one participant with 342 
78.5% compliance (who provided blood samples in the placebo condition only) was excluded from 343 
analysis, due to being below a pre-set level of 80%, making average compliance 101.4% with a 344 
range of 92.9%-114.3%. 345 
Treatment guess 346 
Chi-Square revealed no significant difference between treatment guesses in the 2 treatment groups: 347 
χ2= .766; df= 1; p= .381. 348 
NIRS parameters 349 
Total haemoglobin (total-Hb): 350 
Planned comparisons revealed that, on day 1, levels of total-Hb were significantly higher after 351 
resveratrol, compared to placebo, during the 2-minute epochs spanning 35-38 min post-dose 352 
(35/36min [p=0.003], 37/38 min [p=0.008]) of the absorption period and the epochs spanning 75-78 353 
min (75/76 min [p=0.008], 77/78 min [p=0.005] of the post-dose task period. No significant 354 
differences were found between resveratrol and placebo on day 28. 355 
Oxygenated haemoglobin (oxy-Hb): 356 
Planned comparisons revealed that, on day 1, levels of Oxy-Hb were significantly higher in the 357 
resveratrol condition, compared to placebo, during the 2-min epochs commencing 23 [p=0.002], 27 358 
[p=0.005], 33 [p=0.002], 35 [p=0.001] and 37 [p=0.009] min post-dose of the absorption period and 359 
the epochs spanning 41-44 mins (41/42 min [p=0.006]), 43/44 min [p=0.001]), 53-54 min 360 
[p=0.001], 61-68 min [p= 0.0008; 0.001; 0.007 and 0.001 respectively], 71-72 min [p=0.003], and 361 
75-78 min (75/76 min [p=0.0002], 77/78 min [p=0.0002]) of the post-dose task period. No 362 
significant differences were found between resveratrol and placebo on day 28. 363 
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Deoxygenated haemoglobin (deoxy-Hb): 364 
Planned comparisons revealed that, on day 1, levels of deoxy-Hb were significantly higher in the 365 
placebo condition, compared to resveratrol, during the  2-minute epochs commencing 27 [p=0.001], 366 
29 [p=0.006] and 35 [p=0.003] min post-treatment in  the absorption period and the epochs 367 
commencing 43 min [p=0.004] min, and spanning 51-54 min (51/52 min [p=0.0002], 53/54 min 368 
[p=0.004], and those spanning 61-72 min (61/62 [p=0.001], 63/64 [p = 0.003], 65/66 [p = 0.0005], 369 
67/68 ; [p = 0.002], 69/70 [p = 0.004], 71/72 [p = 0.0008] respectively) and those spanning 75-80 370 
min 75/76 [p=0.001], 77/78 [p = 0.003] 79/80 [p = 0.004] respectively) of the post-dose task period. 371 
No significant differences were found between resveratrol and placebo on day 28. 372 
Mean total-, oxy- and deoxy-Hb levels for placebo and resveratrol, across day 1 and day 28, are 373 
shown in figure 2. 374 
 375 
 376 
Figure 2. about here 377 
 378 
 379 
TCD parameters 380 
No significant acute chronic or gross chronic effects were observed with any of the 4 TCD 381 
parameters (Mean velocity; Peak systolic velocity; Diastolic velocity; and Pulsatility index).  382 
Cognitive task performance  383 
1. Pure chronic ANOVA 384 
The results of the ANOVA on day 28 pre-dose data (converted to change from day 1 baseline) 385 
comparing performance between 500mg resveratrol and placebo, demonstrated a significant effect 386 
of treatment for the 3-Back task in terms of the  % of correct responses (F (1,40)= 8.60, p=.006) 387 
with better performance in the resveratrol condition as compared to placebo. 388 
2. Acute, chronic and superimposed ANOVA 389 
The results of the treatment x repetition x day ANOVA are as follows. Note that, for brevity, only 390 
those significant main and/or interaction effects involving treatment are described here but see 391 
supplementary materials for all ANOVA F and P value tables. 392 
7s incorrect: Analysis revealed a main effect of treatment (F (1, 39)= 6.40, p=0.016) (with the 393 
mean for number of serial 7s incorrect responses for placebo, overall, higher than the mean for 394 
14 
 
500mg resveratrol) and a day x repetition x treatment interaction (F (3, 117)= .260, p=0.034). Post-395 
hoc comparisons (Bonferroni corrected) revealed a significant difference on day 1 at repetition 4 396 
(p=.005) and trends for differences on day 1 at repetition 2 (p= .073) and on day 28 at repetition 3 397 
(p= .070). The mean number of incorrect responses was lower in the 500mg resveratrol condition in 398 
all 3 cases.  399 
17s correct: The ANOVA revealed an interaction between day x treatment x repetition (F (3, 117)= 400 
3.45, p=0.019). Post-hoc comparisons revealed significant differences on day 28 at repetition 1 and 401 
repetition 3 (both p=0.04) with the mean number of serial 17s correct completions higher in the 402 
placebo condition in both cases.  403 
17s incorrect: The ANOVA showed a main effect of treatment (F (1, 39)= 5.79, p=0.021) (with the 404 
mean number of 17s subtraction incorrect responses, overall, higher in the placebo condition as 405 
compared to 500mg resveratrol). An interaction between repetition x treatment (F (3, 117)= 3.55, 406 
p=0.017) was also observed. With regards the repetition x treatment interaction, post-hoc 407 
comparisons revealed only one significant comparison between treatments at the 4th repetition on 408 
day 28. Here the mean number of incorrect responses was higher (p=0.003) in the placebo 409 
condition.  410 
General health 411 
There were no significant treatment related differences on the General Health Questionnaire (GHQ) 412 
or its subcomponents. 413 
Sleep 414 
There were no significant treatment related differences on the Pittsburgh Sleep Quality Index 415 
(PSQI) or its subcomponents. 416 
Mood 417 
A significant treatment effect was observed for the ‘fatigue’ measure alone (F (1, 52)= 9.37, p= 418 
0.003); derived from the Profile of Mood States (POMS) questionnaire. Further analysis with 419 
Bonferroni corrected post-hoc student t tests demonstrated that subjective ratings of fatigue were 420 
significantly lower for resveratrol on day 7 (p=0.04), day 21 (p=0.013) and day 28 (p=0.001). A 421 
move towards a trend was also evinced for day 14 (p=.097). See supplementary materials for 422 
average weekly ratings on POMS questionnaire and ANOVA F and P value tables.  423 
 424 
 425 
 426 
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Blood pressure 427 
1. Pure chronic ANOVA 428 
The results of the ANOVA on day 28 pre-dose BP measurements (converted to change from day 1 429 
baseline) comparing readings between 500mg resveratrol and placebo, demonstrated only a 430 
significant effect for diastolic BP (F (1, 28)= 5.86, p=0.022) with levels higher in the resveratrol 431 
condition. 432 
2. Acute, sub-chronic and superimposed ANOVA 433 
No significant effects were observed for systolic BP or HR. For diastolic BP, a significant 434 
interaction between treatment x day was evinced (F (1, 22)= 6.61p=0.017) which revealed only 1 435 
significant comparison, in the placebo condition, between day 1 and day 28, at the 40 minutes PD 436 
measurement (p=0.46). Here the mean was higher overall on day 28 compared to day 1. 437 
See supplementary materials for BP values and ANOVA F and P value tables. 438 
 439 
Plasma analysis (total metabolite levels) 440 
A significant effect of time was observed (F (1.35, 8.10)= 7.50, p= 0.02) for levels of total 441 
resveratrol metabolites (the sum of Resveratrol 3-O-sulfate and Resveratrol 4’- and 3-O-442 
glucuronides) with pairwise comparisons revealing that day 1 post-dose levels were higher than day 443 
1 baseline (p=0.023), that day 28 pre-dose levels were higher than day 1 baseline (p=0.033) and that 444 
day 28 post-dose levels were higher than both day 1 baseline (p=0.003) and day 28 pre-dose levels 445 
(p=0.005). All 3 metabolites followed this same pattern of significance and so, for brevity, only 446 
total metabolite levels are reported here. 447 
No resveratrol (in any form) was found in baseline samples on day 1, indicating that all volunteers 448 
did not consume resveratrol containing products before the study. No aglycone resveratrol was 449 
quantifiable in plasma at any time-point, on either day. Resveratrol 3-O-sulfate was the 450 
predominant metabolite in all volunteers, contributing 73-77% of total metabolites. The 4’- and 3-451 
O-glucuronide forms evinced roughly equal contributions to the remaining metabolites in 452 
circulation.  453 
Mean plasma concentration values (µM) for resveratrol metabolites at baseline and post-dose (110 454 
minutes after administration) on day 1 and, after daily 500mg consumption, on day 28 shown in 455 
figure 3. 456 
 457 
Figure 3. about here 458 
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DISCUSSION 459 
In summary, the results here show that whilst a single dose of 500mg trans-resveratrol can 460 
modulate CBF parameters in the frontal cortex in a pattern consistent with increased blood flow, 461 
supplementation for 28 days does not result in any clear improvements in cognitive function, 462 
despite an increase in plasma metabolites levels. However, there was evidence of significantly 463 
reduced fatigue and higher diastolic BP following extended supplementation. No modulation of 464 
subjective sleep quality, health or chronic CBF was observed.  465 
The chronic 28 day dosing paradigm utilized in the current paper was designed to address the 466 
potential ineffectiveness of resveratrol at eliciting cognitive performance effects after acute, bolus 467 
supplementation(2, 33). The hypothesis being that chronic consumption of resveratrol might increase 468 
exposure to resveratrol; a polyphenol with known low bioavailability following acute 469 
administration(9). This increased exposure may be expected to enhance the biological activity of 470 
resveratrol; specifically, of importance here, those with direct and/or indirect effects on cognitive 471 
function. However, analysis demonstrated that the only cognitive task measure to evince a pure 472 
chronic effect (derived by the comparison of changes in performance between resveratrol and 473 
placebo between day 1 baseline and day 28 pre-dose) was N-Back % correct: i.e. after 28 days 474 
supplementation, participants in the 500mg resveratrol condition completed significantly more 475 
correct 3-Back responses before taking their day’s treatment, as compared to placebo. No effects on 476 
this measure were observed following consumption of treatment on day 1 or day 28 nor were any 477 
effects observed on the other accuracy sub-measure assessed here. The results of acute and 478 
chronic/superimposed analysis revealed that, on day 28, participants in the resveratrol condition 479 
performed slower, achieving less correct responses on the serial 17 subtractions task. However, on 480 
day 1 and day 28, participants in the same condition also performed more accurately (less incorrect 481 
responses) on the serial 7 and serial 17 subtraction tasks. Whilst these results suggest a speed 482 
accuracy trade-off, closer inspection of these significant main effects highlights an inconsistent and 483 
difficult to interpret pattern, with the effects on the serial 7 task restricted to the 4th task battery 484 
repetition on day 1 only and the 1st, 3rd and 4th repetitions, on day 28, for the effects on the serial 17 485 
subtraction task; where both higher and lower performance was seen in the resveratrol condition. 486 
Due to the lack of any clear pattern of results in both the acute and chronic effects of resveratrol on 487 
cognition here (and indeed the previous two studies assessing the effects of resveratrol on cognitive 488 
function), it is important to regard these results with caution. It may be that the relatively small 489 
sample here is masking a real effect, or a clearer effect, of resveratrol or it may be that a number of 490 
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type I errors have inflated expectations. Nevertheless, only a tightly controlled, crossover study with 491 
greater power would be able to address this issue. 492 
The current study demonstrates that 500mg trans-resveratrol is able to augment the CBF response 493 
to cognitive task demands, relative to placebo, after acute, oral, administration to healthy human 494 
participants. This acute augmentation manifested in small, significantly higher levels of total-Hb, 495 
indicative of increased CBF, at the ends of the absorption- and post-dose task periods and a 496 
consistent pattern of significantly higher levels of oxy-Hb across some of the absorption- and post-497 
dose task periods following the first dose of resveratrol on day 1. Levels of deoxy-Hb were also 498 
significantly lower in the resveratrol condition, as compared to placebo. This latter finding is 499 
directly opposite to that reported previously(2, 33) and is contrary to the hypothesis that resveratrol 500 
would facilitate increased oxygen extraction due to its reported effects on oxidative 501 
phosphorylation(36). No clear reason for this anomalous finding can be offered at present but it may 502 
be notable that whilst the previous two aforementioned resveratrol/NIRS studies by this lab were 503 
crossover studies, the current is the first to utilize a between-subjects design and this may introduce 504 
an unanticipated degree of variability in CBF parameters. In contrast to day 1, the consumption of 505 
the resveratrol treatment on day 28 was not found to have an acute effect on any of the CBF 506 
parameters. As noted above, CW-NIRS generates concentration change, rather than quantitative 507 
data, and therefore only provides a measure of acute changes in haemodynamics during each 508 
discrete recording session. It therefore provides no direct measure of any changes that have taken 509 
place between recording sessions, in this case as a consequence of chronic resveratrol 510 
supplementation. The lack of an effect here may then reflect several distinct possibilities. It may, of 511 
course, reflect a simple attenuation of the acute effects seen following the first dose of resveratrol 512 
on day 1. However, it could equally reflect either the raised levels of resveratrol metabolites seen 513 
pre-treatment on day 28, which may have precluded a further acute effect of an additional dose on 514 
day 28; or it may indicate that a gross (undetected) change in CBF parameters had already taken 515 
place, attenuating the possibility of any additional acute effects of day 28’s treatment. 516 
In the current study, TCD was also incorporated to provide a measure of chronic CBF. This 517 
technique provides an absolute quantitative measure of CBF, (in this case as indexed by CBF 518 
velocity (CBFV) in the right middle cerebral artery) which was intended to elucidate any gross 519 
chronic changes in CBF as a consequence of resveratrol supplementation. No significant changes in 520 
CBFV were observed with TCD, suggesting a simple absence of modulation of CBF by resveratrol 521 
However, this interpretation should be tempered by several considerations. The first is that the 522 
recording period was much shorter (at 5 minutes) than for NIRS and it was undertaken entirely at 523 
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rest, with no data collected during the period of task-performance during which resveratrol has been 524 
shown to have its most pronounced effects. Secondly, whilst the NIRS was used to measure local 525 
changes in CBF in the upper layers of the frontal cortex during tasks which activate this brain area, 526 
the right middle cerebral artery supplies the entire right side of the cortex. Given this, any 527 
vasodilatory effects restricted to the locality of neural activity (in this case the prefrontal cortex) 528 
may have been swamped in the gross blood flow. Potential reasons for a lack of significant CBFV 529 
changes include the relatively short recording period with the TCD: 5 minutes, yielding only 2 530 
measurements per minute, which may simply be to narrow a window to detect effects. The TCD 531 
recording periods were also conducted during times of minimal cognitive demand (pre and post the 532 
cognitive task periods) and, as such, metabolic substrate demands would have been less during 533 
these periods and an increase in the hemodynamic response unnecessary. Ideally the TCD and 534 
NIRS would both have been used to record concomitantly throughout the absorption and cognitive 535 
task periods. Unfortunately, due to the physical constraints of the equipment utilized here, this was 536 
not possible. 537 
The current study does, however, report vascular effects of resveratrol in the periphery on day 28; 538 
with the analysis of pure chronic effects (derived by comparing change from day 1 baseline BP 539 
measurements between resveratrol and placebo to pre-treatment on day 28) demonstrating higher 540 
diastolic BP in resveratrol-supplemented participants. No pre-treatment baseline differences in BP 541 
readings, nor acute effects of treatment within day 1 or day 28 were observed. This finding is 542 
intuitively unexpected as resveratrol has previously been shown to be a vasodilator(6, 37); a 543 
phenomenon associated with lowered BP. Whether resveratrol can act as a vasoconstrictor is, at 544 
present, unknown but it may be noteworthy that structurally similar polyphenols, such as the tea 545 
polyphenol epigallocatechin-3-gallate (EGCG), can act both as both vasodilators and 546 
vasoconstrictors depending on dose and the time of assessment(38). EGCG has also been 547 
investigated with regards its cognitive and CBF effects in humans, with a single dose of 135mg, 548 
leading to a significant reduction in CBF as compared to placebo; which might indeed be suggestive 549 
of vasoconstriction. 550 
No significant differences between treatments, or within-treatment changes, were observed with 551 
subjective perceptions of general health (as assessed by the GHQ) or sleep (as assessed by the 552 
PSQI). With regards subjective perceptions of mood, the only variable on the POMS questionnaire 553 
which evinced any significant difference was ‘fatigue’ which remained significantly lower across 554 
the entire 28 day period in the resveratrol condition, as compared to placebo. Little research exists 555 
regarding the effects of polyphenols on mood but this anti-fatigue effect may find an explanation in 556 
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in vitro and animal work which reports the ability of resveratrol to inhibit Monoamine Oxidase-A 557 
and B (MAO-A/B) activity. This inhibition was reported to lead to an increase in monoamine 558 
neurotransmitter concentrations, namely 5-hydroxytryptophan (5-HT), noradrenaline and dopamine, 559 
with a concomitant improvement in mood; similar to that seen with imipramine and fluoxetine, in 560 
mice(18). Interestingly quercetin, another red wine polyphenol, also shows anti-fatigue activity 561 
through increased energy expenditure and endurance capacity in mice(39, 40 respectively) and power 562 
output in elite male cyclists when part of a cocktail of supplemented compounds(41). Mechanisms 563 
include increased blood flow; due to vasorelaxation(42), and oxygenation; with Davis et al.(40) also 564 
reporting SIRT-mediated increases in mitochondrial gene expression in brain and skeletal muscles. 565 
Both mechanisms are shared with resveratrol(36, 42) and could explain the increased energy levels 566 
seen here. It is worth noting here that, whilst there was no statistically significant difference in 567 
baseline (pre-dose on day 1) levels of fatigue between resveratrol and placebo participants, the 568 
baseline values were nevertheless numerically higher in the former group (8.04 compared to 5.54 569 
respectively) which might suggest that this effect represents a return to normal levels for the 570 
resveratrol group following an unusually high baseline.  571 
Analysis of the plasma samples, taken from a sub-sample of 7 participants from the resveratrol 572 
condition on day 1, demonstrated increases in acute resveratrol metabolite levels post-dose very 573 
similar to those seen in a previous study conducted by this lab(2). Pre-dose levels of metabolites on 574 
day 28 were also significantly higher than those seen pre-dose on day 1, suggesting that chronic 575 
consumption results in an accumulation of resveratrol metabolites in plasma. They subsequently 576 
increased following day 28’s treatment, and again ended at a significantly higher level than post-577 
dose on day 1.  Pre- and post-dose levels of resveratrol on day 28 were significantly higher than 578 
baseline levels on day 1 and, within day 28, post-dose levels were significantly higher than pre-dose 579 
levels. Taken together, these findings suggest (hence their presence prior to treatment 580 
administration on day 28), and that this may amplify the increase following acute administration 581 
(hence numerically higher levels at day 28 post-dose compared to day 1 post-dose). That the day 1 582 
baseline mean levels were 0 does render this comparison, statistically, problematic. However, 583 
disregarding statistical significance, the fact that metabolites were present on day 28 at all 584 
(considering that levels were 0 at baseline on day 1) is indicative that an increase in plasma levels of 585 
resveratrol had taken place. This novel finding of accumulating levels of resveratrol metabolites as 586 
a consequence of chronic administration certainly warrants further investigation with larger 587 
samples, as previous acute dose research does not suggest that plasma metabolites should still be 588 
present beyond 24hrs(9), or certainly not at the levels seen here at pre-dose on day 28(10). It may be 589 
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possible that these effects are the result of some other, unknown factor/s; for instance the 590 
consumption by participants of more resveratrol containing products or an additional resveratrol 591 
capsule prior to attending the laboratory on day 28. However, this seems unlikely, and is argued 592 
against by the participants’ treatment diaries and a capsule count.   593 
The methodology of the current study had a number of strengths and limitations. The nature of the 594 
paradigm; namely the timeframe involved and the use of equipment which dictates individual 595 
testing (i.e. the NIRS and TCD), necessarily means that the sample size is somewhat restricted for 596 
outcome measures like cognitive performance which ideally require a larger sample than the 597 
physiological measures. In this study the issue was exacerbated by the loss of a number of sets of 598 
data (due largely to an equipment failure) which reduced the number of cognitive performance data 599 
sets. This renders interpretation of the cognitive data more difficult, but an argued strength of this 600 
paper is the caution with which the authors have regarded such data. Another limitation relates to 601 
the equipment utilized here to measure CBF. As noted above CW-NIRS only generates acute 602 
concentration change data, and therefore the question that it was used to address on day 28 of the 603 
current study was: “Are the acute haemodynamic effects of the single dose of resveratrol taken on 604 
day 28 the same, or different, to those seen following the first dose taken on day 1”. The results 605 
showed that there were no acute effects on day 28, so they were different. However, the difficulty in 606 
interpreting this finding further is that this could reflect an attenuation of the acute effects over time, 607 
but it could equally be the result either of the raised levels of resveratrol metabolites already seen 608 
prior to taking the day 28 treatment, or indeed unmeasured chronic effects on CBF. To address the 609 
last of these points TCD was incorporated as a measure of chronic changes of absolute CBFV, but 610 
this measure showed no effect- although again this could be due to methodological issues (including 611 
measuring at rest, rather than during task performance, and the diffuse rather than local nature of the 612 
measurement). It would therefore be advantageous to revisit the question of the chronic effects of 613 
resveratrol on CBF using the more recently introduced ‘quantitative’ NIRS, which, as the name 614 
suggests, generates quantitative, rather than concentration change data. In terms of strengths, the 615 
current paper incorporated a range of methodologies in order to answer the, hitherto unaddressed 616 
question, as to whether resveratrol can engender chronic cognitive effects. This is also the first 617 
paper to show that repeated consumption of resveratrol can lead to cumulative plasma levels at a 618 
dose which is recommended by many over-the-counter resveratrol products. 619 
In conclusion, the current study reports that chronic, 28 day supplementation of 500mg trans-620 
resveratrol results in significantly reduced fatigue and higher diastolic BP, but does not modulate 621 
sleep, health or chronic CBF. The single, chronic, cognitive effect evinced by resveratrol and the 622 
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confusing pattern of acute effects, should be treated with caution. This study is the first to suggest 623 
that chronic resveratrol consumption could result in cumulative plasma levels in healthy humans 624 
after oral administration. 625 
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Tables 
Table 1. Participant composition 
 
 
 
 
 
 
 
 
 
 
 
 
Measure            
(Number participants) 
Female/Male 
Mean age    
(Age range) 
Right handed/ 
Left handed 
Placebo/ 
Resveratrol 
Overall recruited 
(N=60) 
51/9 20.52 (18-29) 53/7 30/30 
Cognitive performance 
(N=41) 
36/5 20.00 (18-27) 35/6 19/22 
NIRS (N=46) 39/7 20.45 (18-29) 39/7 24/22 
TCD (N=46) 40/6 20.08 (18-29) 40/6 21/25 
Blood pressure (N=24) 21/3 20.75 (18-29) 21/3 15/9 
GHQ (N=53) 45/8 20.17 (18-29) 46/7 28/25 
POMS (N=54) 46/8 20.07 (18-29) 47/7 28/26 
PSQI (N=53) 45/8 20.15 (18-29) 47/6 28/25 
Food consumption 
(N=55) 
47/8 20.15 (18-29) 48/7 29/26 
Treatment guess 
(N=57) 
49/8 20.25 (18-29) 50/7 28/29 
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Legends 
Table1.  
Table displays number of participants included in each measure. Sixty participants were 
originally recruited to take part in all aspects of assessments apart from the blood pressure 
measurement which utilized only 30 participants due to the potential disruption this may have 
caused to NIRS measurement. Reasons for excluding data from analyses include: technical 
problems with equipment (affecting aspects of 12 cognitive performance data sets, 14 NIRS, 
14 TCD recordings (namely not being able to locate a consistent, 5 minute, blood flow trace 
in the latter and data which was outside of the calculated standard deviations of this cohort, 
and may suggest an ill-fitting headband, with regards NIRS) and 6 blood pressure readings) 
and participants not complying with proper completion of measures/ omitting to respond 
(affecting aspects of 7 cognitive performance data sets, 7 responses from the GHQ, 6 from 
the POMS, 7 from the PSQI, 5 from the food consumption questionnaire and 3 from the 
treatment guess response). 
 
Figure 1. 
Upon arrival participants completed 4 questionnaires (a food consumption questionnaire, the 
GHQ, POMS and the PQSI) which they answered in relation to the previous 7 days and 
completed every 7 days during the supplementation period. Participants then gave a blood 
pressure reading or an intravenous blood sample which was immediately followed by a 5min 
rest. A 5min recording of cerebral perfusion in the MCA was then taken with the TCD. The 
NIRS headband was then positioned and 20min of baseline tasks commenced. A 10min rest 
then followed during which participants watched a non-arousing DVD. Participants then 
consumed their treatment capsule and continued to watch the DVD for a further 40min 
absorption period. A blood pressure reading was then taken from a sub-sample of participants 
and 36mins of post-dose tasks commenced. The NIRS headband was removed and a further 
blood pressure reading taken, followed by a short break, before the 2nd TCD recording was 
conducted. Following the TCD recording the aforementioned sub-section of participants 
provided a blood sample and left the lab.  
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Figure 2. 
Mean (±SEM), change from baseline, concentration changes in levels of (top) total 
haemoglobin (total-Hb), (middle) oxygenated-haemoglobin (oxy-Hb) and (bottom) 
deoxygenated-haemoglobin averaged across two minute epochs during a 40min absorption 
period and subsequent 40 mins of cognitive task performance following placebo or 500mg 
resveratrol on day 1 and day 28 (N=46). Significance planned comparisons (Bonferroni 
corrected) between resveratrol and placebo of data from each 2-min epoch is indicated by * 
(P= <.05) and ** (P= <.01). 
Figure 3. 
Graph displays mean plasma concentration (µM) values (with SEM error bars) of resveratrol 
metabolites in plasma at baseline and post-dose (110mins post administration) on day 1 and 
day 28, after 500mg trans-resveratrol, in 7 healthy, young adults. Significance on graph 
demonstrated for total metabolites, with * (P=<.05) and ** (p=<.01), although all 3 
metabolites demonstrate the same pattern.  
 
